Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies using its proprietary epicutaneous immunotherapy (EPIT) platform. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on immunology and allergy-related diseases. DBV Technologies’ lead product candidate is Viaskin Peanut, a skin-applied patch designed to desensitize patients with peanut allergy, particularly children.
Founded in 2002 in France, DBV Technologies has evolved from a platform-focused biotech into a late-stage clinical company centered on food allergy immunotherapy. Its strategy is built around addressing significant unmet medical needs in allergy treatment through non-invasive, patient-friendly delivery methods. The company’s differentiation lies in its EPIT technology, which delivers allergens through intact skin without systemic exposure, aiming to improve safety compared with traditional immunotherapy approaches.
Business Operations
DBV Technologies’ operations are organized around the research, development, and potential commercialization of EPIT-based product candidates. The company does not currently generate commercial revenue and relies primarily on equity financing and strategic funding to support its clinical development programs. Its core business activities include clinical trials, regulatory engagement, manufacturing scale-up planning, and intellectual property management related to its patch-based technology.
Operations are conducted through the parent company in France and its U.S. subsidiary, DBV Technologies Inc., which manages North American clinical, regulatory, and corporate activities. The company controls proprietary manufacturing processes for its Viaskin patches and collaborates with contract research organizations, clinical trial sites, and specialized manufacturers. As of publicly available disclosures, DBV Technologies does not report material joint ventures but maintains multiple clinical and research partnerships supporting trial execution.
Strategic Position & Investments
DBV Technologies’ strategic direction is centered on advancing Viaskin Peanut toward regulatory approval in major markets, particularly the United States and Europe. Growth initiatives focus on completing late-stage clinical trials, engaging with regulatory authorities, and preparing for potential commercialization, including post-approval studies and market access planning. The company has also explored lifecycle expansion of its EPIT platform into other food allergies, such as milk and egg, though these programs are at earlier stages or subject to prioritization based on resources.
The company has made substantial investments in clinical development infrastructure and intellectual property rather than pursuing large-scale acquisitions. Its most significant assets are its proprietary EPIT technology and clinical data portfolio. Emerging areas of focus include optimizing patch dosing, treatment duration, and patient adherence, as well as evaluating EPIT’s applicability to broader immunological indications. Where development timelines or regulatory outcomes are uncertain, data inconclusive based on available public sources.
Geographic Footprint
DBV Technologies is headquartered in France, with significant operational presence in the United States, which represents its most critical target market. The U.S. operations support clinical trials, regulatory interactions with the FDA, and investor relations, reflecting the strategic importance of potential U.S. approval for Viaskin Peanut.
Beyond Europe and North America, the company’s footprint is primarily clinical rather than commercial, with trial sites and regulatory engagement extending to selected countries in Europe and other regions as required for multinational studies. DBV Technologies’ international influence is largely driven by its clinical development programs rather than established sales or manufacturing operations outside its core regions.
Leadership & Governance
DBV Technologies is led by an executive team with experience in biotechnology, pharmaceuticals, and clinical development, emphasizing regulatory rigor, patient safety, and long-term value creation. The leadership philosophy centers on disciplined clinical execution, transparent regulatory engagement, and focused allocation of capital toward programs with the highest probability of approval and impact.
Key executives include:
- Daniel Tassé – Chief Executive Officer
- Michel Vounatsos – Chairman of the Board
- Andreas Kueppers – Chief Financial Officer
- Pierre-Henri Benhamou – Chief Medical Officer
- Laurent Martin – Chief Operating Officer
The board and management structure reflect governance standards consistent with publicly listed biopharmaceutical companies in both European and U.S. markets, with oversight focused on clinical risk management, financial discipline, and shareholder interests.